

#### Completed studies

1. Mycophenolate Mofetil and Daclizumab in New Onset Type 1 Diabetes;
  - a. Diabetes Care. 2010 Apr;33(4):826-32. doi: 10.2337/dc09-1349.
2. Mixed Meal Tolerance Test versus Glucagon Stimulation Tests
  - a. Diabetes Care. 2008 Oct;31(10):1966-71. doi: 10.2337/dc07-2451
3. Validation and Reproducibility of Islet Reactivity by T cell assays in Type 1 Diabetes
  - a. Diabetes. 2009 Nov;58(11):2588-95. doi: 10.2337/db09-0249.
4. Rituximab in New Onset type 1 diabetes
  - a. N Engl J Med. 2009 Jan; 361:2143-2152. *PubMed PMID:* 19940299.
5. Abatacept in New Onset Type 1 diabetes
  - a. Lancet. 2011 Jul; 378(9789):412-419. *PubMed PMID:* 21719096. *PMCID:* PMC3462593.
6. GAD vaccination in new onset type 1 diabetes
  - a. Lancet. 2011 Jul; 378(9788):319-327. *PubMed PMID:* 21714999. *PMCID:* PMC3580128.
7. Meticulous Metabolic control in new onset type 1 diabetes
  - a. Diabetes Care. 2013 Dec;36(12):4030-5. doi: 10.2337/dc13-1074.
8. Canakinumab in new onset type 1 diabetes
  - a. Lancet 2013 June 1; 381(9881): doi:10.1016/S0140-6736(13)60023-9.
9. Nutritional Intervention to Prevention Diabetes in genetically at risk newborns
  - a. *Pediatr Diabetes*. 2015 Jun;16(4):271-9. doi: 10.1111/pedi.12170. Epub 2014 Jul

#### Ongoing Studies

1. TN01: TrialNet Pathway to Prevention.
  - a. Natural history study of antibody positive individuals
2. TN07: TrialNet Oral Insulin Prevention Study
  - a. Placebo controlled randomized trial of 7.5 mg daily oral insulin to prevent diabetes onset in antibody positive individuals with normal glucose tolerance
3. TN10: TrialNet Anti-CD3 Prevention Study
  - a. Placebo controlled randomized trial of one 14 day course of Teplizumab to prevent diabetes onset in antibody positive individuals with abnormal glucose tolerance.
4. TN16: Long Term Follow-Up
  - a. Natural history study of individuals previously followed in TN01 or other TrialNet clinical trials pre or post clinical diagnosis.
5. TN18: Abatacept Prevention Study
  - a. Placebo controlled randomized trial of one year treatment of Abatacept to prevent abnormal glucose tolerance in antibody positive individuals with normal glucose tolerance.
6. TN19: ATG/GCSF Study



## **Trials for which samples have been obtained through TrialNet**

- a. Three arm, placebo controlled randomized trial of one course of ATG with or without six week course of GCSF to preserve beta cell function in newly diagnosed individuals with T1D.
7. TN20: Immune effects of Oral Insulin
    - a. Randomized trial of 65.5 mg daily or 500 mg every other week of oral insulin in antibody positive individuals to determine immune effects of treatment.